PD-1 blockade combined with antiangiogenic therapy has synergistic effects and has initially shown therapeutic effects. involve administering one cycle of TKIs (fruquintinib or regorafenib). Patients will be divided into three
ROCK inhibitors
PD-1 blockade combined with antiangiogenic therapy has synergistic effects and has initially shown therapeutic effects. involve administering one cycle of TKIs (fruquintinib or regorafenib). Patients will be divided into three